MiNDERA Corp., a South San Francisco, CA-based developer of non-invasive molecular diagnostics for dermatology and skin-related cancers, closed a $1m seed financing round.
Backers included Scientific Health Development and other individual investors. Andrew Offer, Managing Director at Scientific Health Development, will be joining MiNDERA’s Board of Directors following the investment.
The company intends to use the funds to further validate its proprietary micro-needle technology and prepare for the launch of its first research products.
Led by Philippe Nore, CEO and co-founder, MiNDERA has developed a proprietary micro-needle device that enables minimally invasive and targeted extraction of biomarkers from the skin, without requiring a skin biopsy. These biomarkers are then eluted and analyzed by molecular techniques including PCR and next-generation sequencing to deliver a molecular profile of the sampled region. The company is pursuing research applications as well as diagnostic applications for skin cancer and other skin diseases.